Tobias Boch

7PUBLICATIONS
45CO-AUTHORS
Haematological tumoursClinical pharmacology and therapeuticsPredictive and prognostic markersCardiology (incl. cardiovascular diseases)Economic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 05, 2025
Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.

Mark Hartmann, Maximilian Schönung, Jovana Rajak

|Nov 14, 2023
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.

Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers

|Jul 24, 2023
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.

Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers

|Jul 12, 2022
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.

Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch

|Mar 16, 2022
Socio-economic burden of disease: Survivorship costs for renal cell carcinoma.

Julia Caroline Michaeli, Daniel Tobias Michaeli, Tobias Boch

|Jan 11, 2022
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.

Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch

Pageof 2